Skip to main content
HealthReportedHighDevelopingFeatured
6.4

Daraxonrasib pill shows tumour elimination in pancreatic cancer trial

Phase trial data for daily oral daraxonrasib shows tumour shrinkage and possible elimination in some pancreatic cancer patients, a disease with historically poor outcomes. Results are early-stage and not yet peer-reviewed or FDA-approved; durability and survival benefit remain unproven. If confirmed, this would mark a major therapeutic advance in one of the deadliest cancers.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

BBC Newsabout 3 hours agoengCredibility 28%View source

Score Breakdown

Mosaic Score6.4
Model confidence0.3
Significance0.8
Source credibility0.3
Source

Related signals

8 found